Andere talen Suven Life Sciences Limited NSE India S.E.

Aandelen

SUVEN

INE495B01038

Vertraagde tijd NSE India S.E. Andere beurzen 05:55:22 15-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
101,6 ^INR	+1,40%		-2,87%	+25,88%

06/05	Suven Life Sciences Limited rapporteert resultaten voor het volledige jaar dat eindigde op 31 maart 2024	CI
06/05	Suven Life Sciences Limited rapporteert resultaten voor het vierde kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	06/05
Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	06/05
Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	15/04
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	06/02
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024	30/01
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	30/01
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	04/11
Suven Life Sciences : October 30, 2023Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant	30-10-23
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy	30-10-23
October 24, 2023Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3	24-10-23
Suven Pharma Appoints New Board and Management Team	30-09-23
Suven Pharma Appoints Sudhir Kumar Singh as CEO	30-09-23
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08-08-23
Suven Life Sciences : July 17, 2023Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.	17-07-23
Suven Life Sciences : Form MGT-7 FY 2022-23	15-07-23
Suven Life Sciences : Annual Report FY 2022-23 (Book)	12-07-23
Suven Life Sciences : Annual Report 2022-2023	12-07-23
Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at the SLEEP-2023 annual meeting	05-06-23
Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)	03-06-23
Suven Life Sciences : June 01, 2023Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA	01-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Suven Life Sciences Limited NSE India S.E.

Aandelen

SUVEN

INE495B01038

Andere talen

Filters